Biopharmaceutical company BioLineRx Ltd. is making waves in the field of oncology with its cutting-edge drug development program. The company's lead candidate, Motixafortide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer. Currently, the drug is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, as well as Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections. The drug is also being explored as a potential treatment for solid tumors and acute myeloid leukemia. Additionally, BioLineRx Ltd. is in the process of developing AGI-134, an immuno-oncology agent that is currently in Phase 1/2a clinical trials for the treatment of solid tumors. The company is also working on BL-5010, a proprietary, pen-like applicator designed for the non-surgical removal of skin lesions. To further its cutting-edge research, the company has entered into a collaboration agreement with MSD for the cancer immunotherapy field and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer. Additionally, BioLineRx has entered into a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel. As the company’s pipeline continues to progress, BioLineRx Ltd. is poised for continued success in the field of oncology.
BioLineRx Ltd.'s ticker is BLRX
The company's shares trade on the NASDAQ stock exchange
They are based in Modi’in, Israel
There are 11-50 employees working at BioLineRx Ltd.
It is https://www.biolinerx.com/
BioLineRx Ltd. is in the Healthcare sector
BioLineRx Ltd. is in the Biotechnology industry
The following five companies are BioLineRx Ltd.'s industry peers: